Transforming Intellectual Property into Strategic Business Assets
COZAREN empowers biopharma and agrochemical innovators to unlock the full potential of their IP. Through AI-driven chemical and biosequence searches, competitive intelligence and strategic advisory, we transform patents into strategic business assets to maximise value, mitigate risk and accelerate market success.
Maximise value. Reduce risk. Move faster.
Company Capabilities Overview
Patent & Competitive Intelligence Searches
Make decisions with confidence. Our patent and market intelligence services deliver critical insights for IP strategy, M&A, licensing and investment due diligence.
​
-
Novelty & patentability searches;
-
Validity & opposition searches;
-
Freedom-to-operate (FTO) analyses; and,
-
IP landscape & trend mapping to benchmark competitors and identify whitespace opportunities.
Due Diligence Support for IP Transactions
High-stakes deals demand precise, risk-informed insights. Partnering with experienced patent attorneys, we provide end-to-end IP due diligence across the lifecycle.
​
We support:
-
Licensing & acquisition evaluations.
-
Investment & partnership negotiations.
-
R&D collaborations & joint ventures.
-
Commercialisation readiness assessments
Patent Portfolio Optimisation & Licensing Opportunities
Your patents should drive growth, not sit idle. We align IP strategy with commercial objectives to maximise revenue, reduce risk, and unlock long-term value.
​
Our services include:
-
Licensing or litigation support to enforce patent rights.
-
Early infringement and litigation risk assessments to reduce exposure.
-
Acceleration of biopharma development and market entry with investor connections.
-
Identification of high-value licensing prospects, markets and R&D partners.
-
Monetisation of non-core or underused IP via licensing, transfer, divestiture or alternative financing.
-
Competitive intelligence to guide portfolio pruning and operational efficiency.
AI-Integrated Biosequence Search Platforms
Harness AI with gold-standard algorithms like BLAST and Smith-Waterman. Our scalable bioinformatics platforms empower IP, R&D and regulatory teams to work faster, smarter and with greater precision. For more, visit: www.genepat.com
Platform capabilities:
-
High-precision protein and nucleotide sequence searches.
-
Complementarity-determining region (CDR) searches.
-
Motif-based searches with up to five mismatches.
-
Hybrid searches combining sequence data and keyword filters.
About Cornelius Enuezie
Cornelius Enuezie, founder of COZAREN GmbH, leverages more than 28 years of experience in biopharmaceutical and agrochemical patents and industry leadership, including roles at Novartis, IMS Health, Teva and Clarivate, to strengthen and elevate your IP strategy.
​
Proven ability to utilise technical knowledge, business acumen, specialist patent search and competitive intelligence research skills to facilitate an excellent record of building effective licensing and patent monetisation programmes and supplementing the revenue-generating activities of biopharmaceutical organisations.
Qualifications
-
Doctorate in Business Administration (DBA)
-
Master of Laws (LLM) in Patent and Technology Law
-
Bachelor of Science degree in Industrial Chemistry
Connect on LinkedIn for insights and networking
Expertise and Achievements
Major career achievements include:
-
Identified 11 patent infringement cases that generated over US$200 million in value for Novartis.
-
Led the execution of patent out-licensing initiatives, resulting in US$650 million in royalties and cost savings for Novartis.
-
Conducted in-depth competitive intelligence that directly influenced Clarivate’s strategic acquisition of SequenceBase.
-
Oversaw the post-acquisition integration of SequenceBase with Derwent Innovation, streamlining customer workflows and driving a 10%+ increase in new subscriptions.
-
Directed the integration of SequenceBase with Clarivate’s Life Science databases, enriching patented biosequence data with value-added commercial, clinical, regulatory, agrochemical, and plant biotechnology insights.
